ICON Public (NASDAQ:ICLR) PT Raised to $367.00

ICON Public (NASDAQ:ICLRGet Free Report) had its target price upped by Robert W. Baird from $363.00 to $367.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target would suggest a potential upside of 13.65% from the company’s previous close.

ICLR has been the subject of a number of other research reports. Truist Financial increased their price objective on shares of ICON Public from $357.00 to $367.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Barclays raised their price target on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Mizuho reissued a “buy” rating and issued a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. Evercore ISI decreased their price target on shares of ICON Public from $350.00 to $330.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Finally, TD Cowen raised their price target on shares of ICON Public from $343.00 to $349.00 and gave the company a “buy” rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $339.89.

View Our Latest Research Report on ICON Public

ICON Public Stock Up 4.3 %

Shares of NASDAQ ICLR opened at $322.92 on Friday. The company has a 50 day simple moving average of $313.81 and a 200-day simple moving average of $294.63. The company has a market capitalization of $26.64 billion, a P/E ratio of 39.28, a P/E/G ratio of 1.44 and a beta of 1.18. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.21 and a quick ratio of 1.21. ICON Public has a 1 year low of $204.38 and a 1 year high of $344.77.

ICON Public (NASDAQ:ICLRGet Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.30 by $0.08. The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.09 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. On average, equities research analysts predict that ICON Public will post 14.41 earnings per share for the current year.

Institutional Investors Weigh In On ICON Public

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its stake in ICON Public by 22.5% in the first quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 32 shares during the period. Pinnacle Bancorp Inc. increased its stake in ICON Public by 110.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 55 shares during the period. Motco increased its stake in ICON Public by 1.5% in the first quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after purchasing an additional 59 shares during the period. First National Bank of Hutchinson boosted its holdings in shares of ICON Public by 5.7% in the first quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock valued at $381,000 after acquiring an additional 61 shares in the last quarter. Finally, Bruce G. Allen Investments LLC purchased a new stake in shares of ICON Public in the fourth quarter valued at about $25,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Company Profile

(Get Free Report)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Stories

Analyst Recommendations for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.